Nexplanon REMS
Frequently Asked Questions
These frequently asked questions (FAQs) cover new information and requirements for clinicians offering Nexplanon. The recently announced Risk Evaluation and Mitigation System (REMS) requirement, described below, applies to all clinicians who procure, insert, or remove Nexplanon.
The American College of Obstetricians & Gynecologists strongly recommends early certification to avoid disruptions in patient access to this highly effective long-acting contraceptive.
Frequently Asked Questions
-
The U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (NDA) for Nexplanon (etonorgestrel implant) in January 2026; the updated label extends the approved duration of use up to 5 years (previously 3 years). This change is supported by newer clinical trial data.
Additionally, the updated label reflects data showing efficacy across a wide range of body mass indexes (BMIs) (including BMI of 30 kg/m2 or greater) and safety/effectiveness in adolescents. In its updated January 2026 approval, the FDA also required the implementation of a REMS.
-
A REMS is required when the FDA determines that additional measures are essential to ensure that the benefits of a medication outweigh its risks. For Nexplanon, the REMS addresses rare complications related to insertion and removal, such as deep insertions and implant migration.
A large post-marketing observational study confirmed the rarity of these events, but the FDA determined risk would be further mitigated through a REMS that ensures consistent, high-quality training. The Nexplanon REMS expands the existing clinical training program and mandates the reporting of insertion- and removal-related events.
-
All clinicians who insert or remove Nexplanon must be certified under the Nexplanon REMS program. Certification is required to order, dispense (via certified pharmacies), and insert or remove the implant. Requirements differ based on prior training and recent experience.
The deadline for currently trained clinicians to obtain REMS certification is August 23, 2026.
-
- Create a Nexplanon REMS account at https://www.nexplanonrems.com/
- Review prescribing information and the Healthcare Provider Guide
- Complete and submit the Healthcare Provider Knowledge Assessment (a brief seven-question quiz) and the Healthcare Provider Enrollment Form online at www.NEXPLANONREMS.com
Certification is immediate after successful completion. The entire process takes about 10 minutes. All certified providers must immediately report any insertion- or removal-related complications to the REMS program. Consider completing the steps early to avoid missing the August 23, 2026, deadline.
-
- Create a Nexplanon REMS account at https://www.nexplanonrems.com/
- Review prescribing information and the Healthcare Provider Guide
- Complete and submit the Healthcare Provider Knowledge Assessment (a brief seven-question quiz) and the Healthcare Provider Enrollment Form online at www.NEXPLANONREMS.com
- Complete additional online didactic training
- Attend in-person practical training (scheduled through the REMS program)
- Pass a hands-on competency validation (checklist)
Certification occurs after completing all steps. All certified providers must immediately report any insertion- or removal-related complications to the REMS program. Consider completing and scheduling the steps early to ensure patient access to the contraceptive implant.
-
The deadline for currently active, previously trained providers to complete the streamlined REMS certification is August 23, 2026. After that date, all clinicians, regardless of experience and training, will need to complete full training. Failure to obtain REMS certification prior to August 23 will result in the loss of active Nexplanon provider status, with the inability to procure, insert, and remove Nexplanon. Reinstatement will require completion of the comprehensive training process.
-
For more information, go to www.NEXPLANONREMS.com or contact the NEXPLANON REMS Coordinating Center at 1-833-NXP-REMS (1-833-697-7367).
References
Nexplanon® (etonogestrel implant), for subdermal use. Highlights of prescribing information. Organon; 2026. Accessed May 11, 2026. https://www.organon.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf
Organon. Nexplanon REMS. Accessed May 11, 2026. https://www.nexplanonrems.com/
Reed S, Do Minh T, Lange JA, Koro C, Fox M, Heinemann K. Real world data on Nexplanon® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA). Contraception 2019;100:31–6. doi: 10.1016/j.contraception.2019.03.052
This information is designed as an educational resource to aid practitioners in assessing their patients’ needs, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org or by calling the ACOG Resource Center.